Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-02. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
== External links == Creatine+Kinase,+Mitochondrial+Form at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
19 February 2013 – SENSEX becomes S&P SENSEX as BSE ties up with Standard and Poor's to use the S&P brand for Sensex and other indices. 13 March 2014 - The SENSEX closes higher than the Hang Seng Index, to become the major Asian stock market index with the highest value, for the first time ever. 22,000, 24 March 2014 – The SENSEX on 10 March 2014 crossed the 22,000 mark for the first time during intra-day trading. However, it was on 24 March 2014 that the index finally closed above the milestone at 22,095.30. 23,000, 9 May 2014 - The SENSEX crossed record 23,000 level for the first time, but close just short of the milestone level, on 9 May 2014. The index would close well above the 23,000 mark during the following session. 12 May 2014 - The SENSEX closed at its record all-time high of 23,551, a rise of 2.42%(+556.77 points) intraday due to continued fund inflows on hopes of a stable government. 24,000, 13 May 2014 - The SENSEX crossed record 24,000 level for the first time, on 13 May 2014 and reached its peak of 24,067.11 due to sustained capital inflows by foreign funds at the domestic bourses and widespread buying by retail investors after exit polls showing the BJP-led NDA forming the government lifted the key indices to new highs. However it closed at a little low at 23,905 points 25,000, 16 May 2014 - The SENSEX crossed record 25,000 level for the first time, on 16 May 2014 and reached its peak of 25,364.71 due to winning of the BJP led NDA government by a staggering record marginal difference of all times. However, it closed well below the 25,000 mark.
Like the genus Lactarius, russulas have a distinctive flesh consistency, which is also reflected in the appearance of the gills and stipe, and normally makes them immediately recognizable. They have no trace of a veil (no ring, or veil remnants on the cap). The gills are brittle except in a few cases, and cannot be bent parallel with the cap without breaking. Hence the genus Russula is sometimes known colloquially as "brittle gills". They have splitting gills and do not exude a milky substance at cut surfaces, contrary to the genus Lactarius. Presence of large spherical cells, 'sphaerocysts', in the stipe is an important characteristic feature to distinguish the members of Russulaceae from other mushrooms. In Russula, the stipe breaks like the flesh of an apple, while in most other families it only breaks into fibres. The spore powder varies from white to cream, or even orange. While it is relatively easy to identify a sample mushroom as belonging to this genus, it is a significant challenge to distinguish member species of Russula. This task often requires microscopic characteristics, and subtle subjective distinctions, such as the difference between a mild to bitter and a mild to acrid flavor. Moreover, the exact phylogenetic relationships of these mushrooms have yet to be resolved in the professional mycological community, and may ultimately depend on DNA sequencing analysis. The following characteristics are often important in identifying individual species:
Sources: en.wikipedia.org
The metals nickel, chromium, and copper coated with silver have been used to make the normally thin-wired e-cigarette heating elements. The atomizers and heating coils possibly contain aluminum. They likely account for most of the aluminum in the e-cigarette vapor. The chromium used to make the atomizers and heating coils is probably the origin of the chromium. Copper is commonly used to make atomizers. Atomizers and heating coils commonly contain iron. Cadmium, lead, nickel, and silver originated from the heating element. Silicate particles may originate from the fiberglass wicks. Silicate nanoparticles have been found in vapors generated from the fiberglass wicks. Tin may originate from the e-cigarette solder joints. Nickel potentially found in the e-cigarette vapor may originate from the atomizer and heating coils. The nanoparticles can be produced by the heating element or by pyrolysis of chemicals directly touching the wire surface. Chromium, iron, tin, and nickel nanoparticles potentially found in the e-cigarette vapor can originate from the e-cigarette heating coils. Kanthal and nichrome are frequently used heating coils which may account for chromium and nickel in the e-cigarette vapor. Metals can originate from the "cartomizer" from the later-generation devices where an atomizer and cartridge are constructed into one unit. Metal and glass particles can be created and vaporized because of the heating of the liquid with glass fiber.
Efforts are ongoing to find medications that either return the ability to make dystrophin or utrophin. Other efforts include trying to block the entry of calcium ions into muscle cells. Recent reports have revealed gut microbiome dysbiosis influencing muscle pathophysiology through the immune system of dystrophin‐deficient mice and managing of gut dysbiosis with sodium butyrate supplementation (NaB) in mdx mice is reported with rescuing muscle strength and halting inflammation. In human clinical studies, epigenetic manipulation as a potential mechanism through gut microbiome balancing yielding clinically encouraging outcome have been reported, warranting further in-depth evaluation in this direction.
==== 1000–1099 ==== Export of Goods (Control) (Amendment) Order 1993 (S.I. 1993/1020) Foreign Satellite Service Proscription Order 1993 (S.I. 1993/1024) Social Security (Consequential Provisions) Act 1992 Appointed Day Order 1993 (S.I. 1993/1025) Cranfield Airport (Designation) (Detention and Sale of Aircraft) Order 1993 (S.I. 1993/1026) Weymouth and Portland Harbour Revision Order 1993 (S.I. 1993/1027) Town and Country Planning (General Permitted Development) (Scotland) Amendment Order 1993 (S.I. 1993/1036) Gaming Act (Variation of Monetary Limits) (Scotland) Order 1993 (S.I. 1993/1037) Town and Country Planning (Use Classes) (Scotland) Amendment Order 1993 (S.I. 1993/1038) Town and Country Planning (General S.I. 1993/1039) Gaming Clubs (Hours and Charges) (Scotland) Amendment Regulations 1993 (S.I. 1993/1040) Reconstitution of the Bedfordshire and River Ivel Internal Drainage Board Order 1993 (S.I. 1993/1041) Glan Conwy-Conwy Morfa Trunk Road (A547) (Previously known as and forming part of The Chester—Bangor Trunk Road (A55)) Detrunking Order 1993 (S.I. 1993/1057) International Finance Corporation (1991 General Capital Increase) Order 1993 (S.I. 1993/1059) Asian Development Bank (Fifth Replenishment of the Asian Development Fund and Second Regularized Replenishment of the Technical Assistance Special Fund) Order 1993 (S.I. 1993/1060) Banking Appeal Tribunal (Scottish Appeals) Amendment Regulations 1993 (S.I. 1993/1061) Financial Assistance for Environmental Purposes Order 1993 (S.I. 1993/1062) A43 Trunk Road (Silverstone Bypass and Slip Roads) Order 1993 (S.I.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.